Results 81 to 90 of about 13,054 (213)

Histone deacetylase inhibitors (HDACi) induce apoptosis and proliferation inhibition in childhood B-cellprecursor acute lymphoblastic leukemia (BCP-ALL) cell lines

, 2012
In dieser Arbeit wurden unterschiedliche HDACi bezüglich ihrer histonacetylierenden und zytotoxischen Wirkung auf unterschiedliche ALL Zelllinien untersucht und charakterisiert.
Kawan, Lars
core   +1 more source

The impact of selective HDAC inhibitors on the transcriptome of early mouse embryos

BMC Genomics
Background Histone acetylation, which is regulated by histone acetyltransferases (HATs) and histone deacetylases (HDACs), plays a crucial role in the control of gene expression. HDAC inhibitors (HDACi) have shown potential in cancer therapy; however, the
Ruiqi Shao, Takayoshi Suzuki, Mikita Suyama, Yuichi Tsukada   +3 more
doaj   +1 more source

Summary of the effects of HDACI treatment on lipolysis, ERK phosphorylation, and PPARγ levels.

, 2013
Summary of the effects of HDACI treatment on lipolysis, ERK phosphorylation, and PPARγ levels.
Juu-Chin Lu (126846), Yu-Tzu Chang (126853), Chun-Ken Lin (443741), Chih-Tien Wang (126861), Zhong-Sheng Wu (443742), Yu-Chun Lin (36446)   +5 more
core   +1 more source

RNA-Seq HAEC + TNFa +HDACi

HAEC treated with HDACi or BCL6 inhibitors, and TNF. RNA-Seq normalized CPMTHIS DATASET IS ARCHIVED AT DANS/EASY, BUT NOT ACCESSIBLE HERE.
Valenzuela, N (via Mendeley Data)
core   +1 more source

Changes in transcript level induced by HDACi.

, 2012
(A) Venn diagram showing genes where transcript levels changed significantly ...
Karl P. Nightingale (174174), Bryan M. Turner (174168), John Halsall (174145), Vibhor Gupta (74280), Laura P. O'Neill (174157)   +4 more
core   +1 more source

Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma

Clinical Epigenetics, 2018
Background Malignant pleural mesothelioma (MPM) is a very rare and highly aggressive cancer of the pleura associated in most cases with asbestos exposure. To date, no really efficient treatments are available for this pathology.
Douae Bensaid, Thibaut Blondy, Sophie Deshayes, Virginie Dehame, Philippe Bertrand, Marc Grégoire, Mohammed Errami, Christophe Blanquart   +7 more
doaj   +1 more source

The therapeutic potential of class I selective histone deacetylase inhibitors in ovarian cancer

Frontiers in Oncology, 2014
Epithelial ovarian cancer remains the deadliest gynecologic malignancy. Despite advances in treatment, new approaches are needed. Histone deacetylases (HDACs) are a family of enzymes that regulate gene expression by removing acetyl groups from lysine ...
Dineo eKhabele
doaj   +1 more source

Abstract 4855: Role of HDACi-induced autophagy in malignant peripheral nerve sheath tumors (MPNST)

, 2010
Malignant peripheral nerve sheath tumors (MPNSTs) are rare tumors that remain incurable mainly due to their high metastatic potential. These biologically aggressive tumors account for 3-10% of soft tissue sarcoma (STS).
Keila E. Torres, Gonzalo Lopez, Juehui Liu, Dina Lev, Raphael E. Pollock   +4 more
core   +1 more source

Design and Synthesis of HDACi Derivatives for Cancer Treatment

Cancer, the second leading cause of death worldwide, entails the unregulated growth and proliferation of abnormal human cells anywhere in the body with the ability to infiltrate and destroy healthy tissue.
Zhao, Qinliang, Wen, Ashley, Tran, Christine   +2 more
core   +1 more source

Complex molecular mechanisms cooperate to mediate histone deacetylase inhibitors anti-tumour activity in neuroblastoma cells

Molecular Cancer, 2008
Background Histone deacetylase inhibitors (HDACi) are a new class of promising anti-tumour agent inhibiting cell proliferation and survival in tumour cells with very low toxicity toward normal cells.
Nardou Katya, Bourloud Katia, Flahaut Marjorie, Meier Roland, Mühlethaler-Mottet Annick, Joseph Jean-Marc, Gross Nicole   +6 more
doaj   +1 more source